An oral combination strategy expands treatment options in metastatic breast cancer. Results from the phase 3 evERA study in the New England Journal of Medicine show that adding giredestrant, a selective estrogen receptor degrader, to everolimus significantly extends time without progression compared with the control approach. The update is a clear example of endocrine-pathway control plus mTOR inhibition, designed to overcome resistance pathways that emerge under standard anti-hormone regimens. For biotech and product teams, the key takeaway is an efficacy signal robust enough to inform competitive positioning in HR-positive metastatic settings where mechanism-matched combinations are increasingly central to differentiation.